1. Aabo K, Adams M, Adnitt P, Alberts DS, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D, Yeap BY (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78: 1479–1487
2. Aapro MS, Pujade-Lauraine E, Lhommé C, Fumoleau P, Kerbrat P, Lentz M-A, Azli N (1994) EORTC Clinical Screening Group: phase II study of Taxotere in ovarian cancer (Abstract). Ann Oncol 5(Suppl 5): 508
3. Aapro MS, Zulian G, Alberto P, Bruno R, Oulid-Aissa D, Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of Taxotere. Ann Oncol 3: 53
4. American Cancer Society (2003) What are the key statistics about ovarian cancer? Available from: URL:
http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_ovarian_cancer_33.asp?sitearea=
[accessed 6 July 2003]
5. Barasoain I, De Ines C, Diaz F (1991) Interaction of tubulin and cellular microtubules with Taxotere (RP 56976), a new semisynthetic analog of Taxol (Abstract). Proc AACR 32: 1952